1844 1919

Cited 0 times in

위염환자에서 글립타이드정Ⓡ 200 mg (Sulglycotide)의 치료 효과- 단일맹검, 무작위 배정, 비교약 대조, 다기관 4상 임상시험 -

Other Titles
 Therapeutic Efficacy of GliptideⓇ(Sulglycotide) on Gastritis-A Single Blind, Randomized, Active Drug Comparative, Multi-center, Phase IV Study- 
Authors
 김지현  ;  윤영훈  ;  이용찬  ;  김병관  ;  김지원  ;  이국래  ;  박영수  ;  김나영  ;  이동호  ;  류지곤  ;  윤용범  ;  조용석 
Citation
 Korean Journal of Helicobacter and Upper Gastrointestinal Research, Vol.5(2) : 233-239, 2005 
Journal Title
Korean Journal of Helicobacter and Upper Gastrointestinal Research
ISSN
 1598-415X 
Issue Date
2005
MeSH
GliptideTM ; Sulglycotide ; Gastirits ; Dyspepsia
Keywords
GliptideTM ; Sulglycotide ; Gastirits ; Dyspepsia
Abstract
Background/Aims: Sulglycotide is a glycopeptide isolated from pig duodenum constituents. Sulglycotide is know to induce increased excretion of bicarbonate and prostaglandins in gastric juice and recent studies have shown various anti H. pylori effect of sulglycotide in vitro and in vivo. The purpose of this study was to assess the therapeutic efficacy and safety of GliptideTM (sulglycotide) in comparison with another mucosal protectants, StillenTM for the treatment of gastritis.
Methods: One hundread and fifty patients with acute or chronic gastritis with various dyspeptic symptoms were enrolled and underwent a single-blind, randomized, active drug comparative trial vs Stillen. Each group received either GliptideTM (oral, 200 mg t.i.d. for 4 weeks, n=76) or StillenTM (oral, 180 mg t.i.d. for 4 weeks, n= 74). Drug effectiveness was evaluated in terms of apparent clinical symptom improvements and follow-up endoscopic scorings for evaluations.
Results: GliptideTM or StillenTM treatment have resulted in endoscopic improvement rates of gastritis by 38.2% vs. 32.4% (ITT) and 47.5% vs. 39.3% (PP) respectively. Both treatments have resulted in the prompt improvements of the dyspeptic symptoms effectively (gliptide group, 63.2% and stillen group, 56.8% respectively, ITT). Endoscopic cure rates in gliptide and stillen groups were comparable to each other (25.0% vs. 20.3% by ITT, 32.2% vs. 26.8% by PP respectively). Endoscopic cure rates and improvement rates as well as symptom improvements indices were not significantly different between GliptideTM and StillenTM treated groups. No significant adverse events were encountered during the study period.
Conclusions: This study clearly shows that the GliptideTM is an effective and safe drug for the treatment of gastritis accompanied by dyspeptic symptoms in Korea.
Files in This Item:
T200503613.pdf Download
DOI
OAK-2005-02092
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jie-Hyun(김지현) ORCID logo https://orcid.org/0000-0002-9198-3326
Lee, Yong Chan(이용찬) ORCID logo https://orcid.org/0000-0001-8800-6906
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/114884
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links